Henan Lingrui Pharmaceutical Co Ltd

SHG:600285 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.70 Billion
CN¥12.50 Billion CNY
Market Cap Rank
#6287 Global
#938 in China
Share Price
CN¥22.05
Change (1 day)
+1.19%
52-Week Range
CN¥20.52 - CN¥24.70
All Time High
CN¥26.75
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Pharmaceutical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orth… Read more

Henan Lingrui Pharmaceutical Co Ltd (600285) - Net Assets

Latest net assets as of September 2025: CN¥3.28 Billion CNY

Based on the latest financial reports, Henan Lingrui Pharmaceutical Co Ltd (600285) has net assets worth CN¥3.28 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.76 Billion) and total liabilities (CN¥2.47 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥3.28 Billion
% of Total Assets 57.04%
Annual Growth Rate 18.17%
5-Year Change 32.65%
10-Year Change 78.67%
Growth Volatility 104.32

Henan Lingrui Pharmaceutical Co Ltd - Net Assets Trend (1997–2024)

This chart illustrates how Henan Lingrui Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Henan Lingrui Pharmaceutical Co Ltd (1997–2024)

The table below shows the annual net assets of Henan Lingrui Pharmaceutical Co Ltd from 1997 to 2024.

Year Net Assets Change
2024-12-31 CN¥3.08 Billion +10.06%
2023-12-31 CN¥2.80 Billion +9.39%
2022-12-31 CN¥2.56 Billion +11.89%
2021-12-31 CN¥2.29 Billion -1.53%
2020-12-31 CN¥2.32 Billion +4.58%
2019-12-31 CN¥2.22 Billion +6.01%
2018-12-31 CN¥2.09 Billion -4.97%
2017-12-31 CN¥2.20 Billion +4.35%
2016-12-31 CN¥2.11 Billion +22.51%
2015-12-31 CN¥1.72 Billion +10.46%
2014-12-31 CN¥1.56 Billion +58.47%
2013-12-31 CN¥984.89 Million +41.31%
2012-12-31 CN¥696.97 Million +1.89%
2011-12-31 CN¥684.01 Million -3.62%
2010-12-31 CN¥709.69 Million +9.91%
2009-12-31 CN¥645.69 Million +17.46%
2008-12-31 CN¥549.72 Million -5.10%
2007-12-31 CN¥579.24 Million +19.02%
2006-12-31 CN¥486.67 Million +1.43%
2005-12-31 CN¥479.80 Million +2.20%
2004-12-31 CN¥469.45 Million +3.93%
2003-12-31 CN¥451.69 Million +8.39%
2002-12-31 CN¥416.74 Million +3.72%
2001-12-31 CN¥401.79 Million -1.63%
2000-12-31 CN¥408.46 Million +557.93%
1999-12-31 CN¥62.08 Million +24.53%
1998-12-31 CN¥49.85 Million +46.73%
1997-12-31 CN¥33.98 Million --

Equity Component Analysis

This analysis shows how different components contribute to Henan Lingrui Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 6989.9% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥1.90 Billion 61.68%
Common Stock CN¥567.12 Million 18.46%
Other Components CN¥610.22 Million 19.86%
Total Equity CN¥3.07 Billion 100.00%

Henan Lingrui Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Henan Lingrui Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Shenzhen FRD Science & Technology Co Ltd
SHE:300602
 		$1.31 Billion
General Insurance Corporation of India
NSE:GICRE
 		$1.31 Billion
Kennedy-Wilson Holdings Inc
NYSE:KW
 		$1.31 Billion
Yusys Technologies Co Ltd Class A
SHE:300674
 		$1.31 Billion
NTT UD REIT Investment Corporation
OTCGREY:PICJF
 		$1.31 Billion
Kerry Properties Limited
PINK:KRYPF
 		$1.31 Billion
Hedef Holdings AS
IS:HEDEF
 		$1.31 Billion
Immunocore Holdings Ltd
NASDAQ:IMCR
 		$1.31 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Henan Lingrui Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 2,791,040,844 to 3,072,526,287, a change of 281,485,443 (10.1%).
  • Net income of 722,550,725 contributed positively to equity growth.
  • Dividend payments of 451,344,714 reduced retained earnings.
  • Share repurchases of 85,097 reduced equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥722.55 Million +23.52%
Dividends Paid CN¥451.34 Million -14.69%
Share Repurchases CN¥85.10K -0.0%
Other Changes CN¥10.36 Million +0.34%
Total Change CN¥- 10.09%

Book Value vs Market Value Analysis

This analysis compares Henan Lingrui Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.05x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 293.87x to 4.05x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1997-12-31 CN¥0.08 CN¥22.05 x
1998-12-31 CN¥0.11 CN¥22.05 x
1999-12-31 CN¥0.14 CN¥22.05 x
2000-12-31 CN¥0.90 CN¥22.05 x
2001-12-31 CN¥0.89 CN¥22.05 x
2002-12-31 CN¥1.84 CN¥22.05 x
2003-12-31 CN¥1.92 CN¥22.05 x
2004-12-31 CN¥1.95 CN¥22.05 x
2005-12-31 CN¥2.01 CN¥22.05 x
2006-12-31 CN¥1.01 CN¥22.05 x
2007-12-31 CN¥1.25 CN¥22.05 x
2008-12-31 CN¥1.12 CN¥22.05 x
2009-12-31 CN¥1.43 CN¥22.05 x
2010-12-31 CN¥1.52 CN¥22.05 x
2011-12-31 CN¥1.49 CN¥22.05 x
2012-12-31 CN¥1.49 CN¥22.05 x
2013-12-31 CN¥1.84 CN¥22.05 x
2014-12-31 CN¥2.84 CN¥22.05 x
2015-12-31 CN¥3.23 CN¥22.05 x
2016-12-31 CN¥3.62 CN¥22.05 x
2017-12-31 CN¥3.71 CN¥22.05 x
2018-12-31 CN¥3.53 CN¥22.05 x
2019-12-31 CN¥3.89 CN¥22.05 x
2020-12-31 CN¥4.07 CN¥22.05 x
2021-12-31 CN¥4.02 CN¥22.05 x
2022-12-31 CN¥4.49 CN¥22.05 x
2023-12-31 CN¥4.93 CN¥22.05 x
2024-12-31 CN¥5.45 CN¥22.05 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Henan Lingrui Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 23.52%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 20.64%
  • • Asset Turnover: 0.70x
  • • Equity Multiplier: 1.63x
  • Recent ROE (23.52%) is above the historical average (13.67%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1997 67.21% 31.05% 0.82x 2.64x CN¥19.44 Million
1998 48.05% 22.18% 0.86x 2.52x CN¥18.97 Million
1999 34.71% 20.72% 0.59x 2.82x CN¥15.34 Million
2000 5.77% 18.02% 0.25x 1.26x CN¥-17.29 Million
2001 6.25% 14.58% 0.31x 1.39x CN¥-15.07 Million
2002 3.15% 6.90% 0.27x 1.68x CN¥-28.40 Million
2003 3.28% 6.00% 0.32x 1.72x CN¥-29.03 Million
2004 3.49% 4.51% 0.41x 1.88x CN¥-28.67 Million
2005 4.07% 4.62% 0.46x 1.92x CN¥-26.89 Million
2006 2.82% 3.28% 0.45x 1.93x CN¥-32.74 Million
2007 12.41% 13.36% 0.55x 1.68x CN¥13.50 Million
2008 1.98% 2.48% 0.44x 1.83x CN¥-42.51 Million
2009 4.67% 6.33% 0.45x 1.63x CN¥-33.40 Million
2010 7.02% 12.74% 0.32x 1.73x CN¥-20.58 Million
2011 4.48% 6.65% 0.37x 1.81x CN¥-36.71 Million
2012 6.25% 7.54% 0.43x 1.91x CN¥-25.47 Million
2013 10.89% 15.34% 0.42x 1.70x CN¥8.64 Million
2014 4.94% 9.22% 0.33x 1.60x CN¥-78.18 Million
2015 7.73% 12.16% 0.40x 1.59x CN¥-38.70 Million
2016 16.57% 24.02% 0.48x 1.43x CN¥137.06 Million
2017 9.99% 11.75% 0.56x 1.52x CN¥-318.61K
2018 11.68% 11.85% 0.66x 1.49x CN¥35.05 Million
2019 13.32% 13.65% 0.65x 1.50x CN¥73.45 Million
2020 14.07% 13.96% 0.67x 1.50x CN¥94.22 Million
2021 15.86% 13.42% 0.71x 1.66x CN¥133.64 Million
2022 18.24% 15.50% 0.69x 1.70x CN¥210.21 Million
2023 20.35% 17.16% 0.69x 1.71x CN¥289.01 Million
2024 23.52% 20.64% 0.70x 1.63x CN¥415.30 Million

Industry Comparison

This section compares Henan Lingrui Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Henan Lingrui Pharmaceutical Co Ltd (600285) CN¥3.28 Billion 67.21% 0.75x $1.31 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million